Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect.

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Our Bureau, Bengaluru Wednesday, July 2, 2025, 16:15 Hrs [IST] Merck is back with its fourth edition of the Merck Young Scientist ...